Specialty pharmaceutical company Ventrus Biosciences files for a $20 million IPO

Ventrus Biosciences, a specialty pharmaceutical company focused on late-stage drugs for gastrointestinal disorders, filed on Wednesday with the SEC to raise up to $20 million in an initial public offering. The New York, NY-based company was founded in 2005 and plans to list on the under the symbol VTUS. National Securities is the lead underwriter on the deal. No pricing terms were disclosed.